WallStreetZenWallStreetZen

NASDAQ: SRPT
Sarepta Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Sarepta Therapeutics earnings were $65.1M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest SRPT earnings report on Mar 31, 2026 announced Q1 2026 earnings of $331.0M, down 217% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, SRPT reported annual earnings of -$713.4M, with -403.3% growth. The next SRPT earnings date is Aug 5, 2026.

SRPT past earnings growth

How has SRPT's earnings growth performed historically?

Company
N/A
Industry
49%
Market
83.56%
SRPT's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
SRPT's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

SRPT earnings history

Current Revenue
$2.2B
Current Earnings
$65.1M
Current Profit Margin
3%

SRPT Return on Equity

Current Company
4.9%
Current Industry
-141.9%
Current Market
13.5%
SRPT's Return on Equity (4.9%)... subscribe to Premium to read more.
High Return on Equity Performance

SRPT Return on Assets

Current Company
1.9%
Current Industry
-13.7%
SRPT is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when SRPT announces earnings.

SRPT Return on Capital Employed

Current Company
0.91%
Current Industry
-9.5%
SRPT has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SRPT vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
SRPT$82.73M$65.06M+20.97%$0.60
MESON/A-$94.37MN/A-$0.74
TSHA-$127.36M-$129.88MN/A-$0.38
GENBN/AN/AN/AN/A
LKFTN/A$575.03MN/AN/A
View Top Biotech Stocks

SRPT earnings dates

Next earnings date
Aug 5, 2026

Sarepta Therapeutics Earnings Reports & History FAQ

What were Sarepta Therapeutics's earnings last quarter?

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 2026 earnings per share (EPS) of $3.15, up 168.48% year over year. Total SRPT earnings for the quarter were $330.96 million. In the same quarter last year, Sarepta Therapeutics's earnings per share (EPS) was -$4.60.

If you're new to stock investing, here's how to buy Sarepta Therapeutics stock.

When does Sarepta Therapeutics report earnings?

The next SRPT earnings call is Invalid Date. Add SRPT to your watchlist to be reminded of Sarepta Therapeutics's next earnings date.

Is Sarepta Therapeutics profitable or losing money?

As of the last Sarepta Therapeutics earnings report, Sarepta Therapeutics is currently profitable. Sarepta Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $65.06 million, a 126.19% decrease year over year.

What was SRPT's earnings growth in the past year?

As of Sarepta Therapeutics's earnings date in Q2 2026, Sarepta Therapeutics's earnings has grown year over year. SRPT earnings in the past year totalled $65.06 million.

What are Sarepta Therapeutics's earnings expectations?

The current EPS estimate for Sarepta Therapeutics's earnings report in Invalid Date is $0.49.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.